Zinc, Fisetin, and Inflammaging: How to Read the New Anti-Inflammatory Supplement Trials

Two publications landed this year that, read together, tell you more about anti-inflammatory supplements than either does alone. A meta-analysis of 18 randomized trials found that zinc supplementation improved insulin resistance and inflammation markers in people with metabolic disease. And a Danish-American team registered the first triple-blind trial of low-dose fisetin in generally healthy adults over 50, with an inflammation biomarker as the primary outcome. Both point at the same target, chronic low-grade inflammation, and both expose the same gap: markers are moving, outcomes are not yet proven.

Inflammaging: The Slow Burn Worth Watching After 40

Researchers call it inflammaging: the gradual rise in circulating inflammatory markers that accompanies aging even in people who feel fine. A 2018 review in Nature Reviews Cardiology by Luigi Ferrucci and Elisa Fabbri identified this chronic inflammation as a significant risk factor for cardiovascular disease, multimorbidity, and frailty. It is not an infection you can feel; it is a background signal that tracks with how fast the machinery wears.

That signal is measurable. Beyond the familiar hs-CRP, researchers increasingly use suPAR (soluble urokinase plasminogen activator receptor), which a 2021 review in Frontiers in Immunology described as a stable marker of systemic chronic inflammation and immune activation, linking multiple age-related conditions. Keep suPAR in mind; it is the number the new fisetin trial is built around.

Zinc: Better Biomarkers, But Not Better Blood Sugar

What the 2026 meta-analysis actually found

The meta-analysis, published in Endocrinology, Diabetes & Metabolism (Loaiza-Giraldo et al., 2026), pooled 18 randomized controlled trials with 1,023 participants who had type 1, type 2, or gestational diabetes, or prediabetes. Compared with placebo, zinc supplementation:

• raised plasma zinc concentrations (mean difference +7.80);
• lowered serum insulin (mean difference -2.50) and HOMA-IR, a standard index of insulin resistance (mean difference -1.10);
• reduced C-reactive protein (standardized mean difference -0.91) and the oxidative-stress marker malondialdehyde (-0.76), while increasing total antioxidant capacity (+1.79).

Those are real, statistically significant shifts in the upstream biology of metabolic aging.

The result the headlines skip

Here is what did not move. As FoundMyFitness noted in its August 2026 analysis of the paper, fasting glucose and HbA1c, the two numbers most people would call "blood sugar control," showed no improvement; the published abstract itself reports gains only in insulin resistance, inflammation, and oxidative stress. The trials averaged about 19 weeks, participants averaged around 44 years old, and all of them had some form of glucose dysregulation. Whether any of this generalizes to a healthy 55-year-old with normal zinc status is simply unknown.

Zinc also has a hard ceiling. The NIH Office of Dietary Supplements sets the adult RDA at 11 mg per day for men and 8 mg for women, with a tolerable upper intake level of 40 mg per day from all sources. Intakes of 50 mg per day or more sustained over weeks can inhibit copper absorption and produce copper deficiency, which damages nerves and blood counts. This is a nutrient where "more" turns against you quickly.

Fisetin: A Senolytic Story Entering Its Human Chapter

Fisetin, a flavonoid found in strawberries, became famous through a 2018 EBioMedicine study (Yousefzadeh et al.) showing that acute or intermittent dosing reduced senescence markers across tissues and extended median and maximum lifespan in mice. That single animal result launched a thousand supplement bottles.

Human data have lagged badly. The Mayo Clinic's AFFIRM-LITE trial (NCT03675724) has been testing high-dose intermittent fisetin, 20 mg per kg on two consecutive days, in frail adults over 70 since 2018; its estimated primary completion is November 2026, and no results have been published yet.

The new protocol, published in Basic & Clinical Pharmacology & Toxicology (Tavenier et al., 2026) by researchers at Copenhagen University Hospital and Duke University, takes the opposite approach: 100 mg of fisetin daily for 7 weeks in generally healthy adults aged 50 and up, triple-blind, placebo-controlled, with the change in plasma suPAR as the primary outcome and adverse events as the secondary one. Note the arithmetic: the Mayo "senolytic" dose works out to roughly 1,500 mg per day for a 75 kg adult, taken in short bursts; the Copenhagen trial tests one fifteenth of that, taken continuously. If you are buying fisetin today, no published human trial tells you which regimen, if either, does anything.

Sorting the Claims: Established, Emerging, Experimental

Established evidence. Chronic low-grade inflammation predicts cardiovascular disease, frailty, and multimorbidity in aging populations. Zinc is essential for insulin production and immune function, deficiency is genuinely harmful, and the 40 mg daily upper limit is well documented. Exercise, sleep, and body-fat reduction remain the interventions with the strongest anti-inflammatory track record.

Emerging evidence. Zinc supplementation improves insulin resistance and inflammation markers in people with existing glucose dysregulation, without yet improving glucose or HbA1c. suPAR is emerging as a trackable marker of inflammaging. Fisetin is senolytic in mice; its first placebo-controlled tests in humans are only now being run.

Personal experimentation. Everything else: taking zinc as a metabolically healthy adult, taking any dose of fisetin, or combining either with other "longevity stack" ingredients. These are n-of-1 experiments, and they deserve to be run like experiments, not like habits.

A Five-Step Way to Test an Anti-Inflammatory Change on Yourself

1. Get a baseline. Ask your physician for hs-CRP plus fasting glucose and fasting insulin, and compute HOMA-IR (glucose in mg/dL times insulin in µIU/mL, divided by 405).
2. Audit intake before supplementing. Zinc lives in oysters, beef, pumpkin seeds, and legumes. If your diet is already adequate, the trial evidence gives you little reason to add more.
3. Change one variable. One supplement, or one training block, or one sleep intervention. Not three at once.
4. Hold it for 8 to 12 weeks. Shorter windows measure noise.
5. Retest and decide. Keep what moved your numbers, drop what did not.

A concrete example: Marc, 54, mostly plant-based eater, logs an hs-CRP of 2.6 mg/L and fasting insulin of 13 µIU/mL. His diet audit shows zinc intake below the RDA, so he adds 15 mg per day, well under the ceiling, changes nothing else, and retests at week 12: hs-CRP 1.8, insulin 10. He still cannot claim causation from one cycle, but he ran a clean loop with observable markers instead of adding another pill on faith. The reference points are public: the CDC and American Heart Association's joint 2003 statement classifies hs-CRP under 1 mg/L as lower cardiovascular risk, 1 to 3 as average, and above 3 as higher.

Mistakes That Ruin the Experiment

• Megadosing zinc indefinitely. Popular 50 mg capsules exceed the 40 mg upper limit on their own and can drive copper deficiency within weeks.
• Importing the mouse dose. Copying rodent fisetin protocols into 1,000 mg-plus "flush" weekends has zero published human efficacy or safety data behind it.
• Judging by a single blood draw. A cold, a hard workout, or a dental issue can spike CRP; confirm any surprising value with a second test a few weeks later.
• Buying the stack before the data. Combined "senolytic complexes" make attribution impossible and multiply unknowns.
• Skipping the deficiency question. The plausible benefit of zinc concentrates in people who lack it; supplementing past sufficiency has no demonstrated upside and a documented downside.

What To Do This Week

Book the three baseline labs. Run the diet audit before you buy anything. If you and your physician decide zinc is worth a trial, stay at or below the RDA-to-40 mg range and set a 12-week retest date now. And put a calendar note on the Copenhagen fisetin trial: for the first time, a rigorous answer on low-dose fisetin and human inflammation is actually on its way. The honest position until then is the one this site exists for: markers justify experiments; only outcomes justify habits.

Thrive Through Time tracks these trials and will cover the fisetin and AFFIRM-LITE results when they publish.

Sources